TNFRSF8 and lymphoma: Although the application of BV in EBV+lymphoma is rarely reported, the above study gives us the insight that BV may become one of the potential combination therapeutic agents for patients with EBV+lymphoma with a deeper understanding of the mechanism of CD30’s role in EBV+lymphoma from the perspective of EBV.